It Was the Best of Times, It Was the Worst of Times
Article, see p 51 I n 1897, Dr Victor Eisenmenger described a 32-year-old man with a history of cyanosis beginning as a child. After death from massive hemoptysis, his autopsy showed a large ventricular septal defect. In the 1950s, Wood 1 began to describe the hemodynamic effects of chronic volume and pressure overload leading to the reversal of a central shunt because of irreversible pulmonary vascular obstructive disease. Wood also recognized that Eisenmenger syndrome (ES) develops in patients with large unrestrictive shunt defects, such as a large ventricular septal defect, large patent ductus arteriosus, or atrioventricular septal defect.
In the subsequent decades, conservative medical management has led to improved survival. The prevalence of ES is also decreasing because surveillance is more standard and surgical repair is more available. In a Nordic cohort, the incidence of ES decreased from 2.5/million inhabitants/year in 1977 to 0.2/million inhabitants/year in 2012. 2 Further, subclassification of congenital heart defects using the Nice World Symposium of Pulmonary Hypertension criteria has revealed disparate survival between congenital heart disease groups. In general, patients with ES live longer than those patients with fully repaired shunts and postoperative pulmonary arterial hypertension (PAH). 3 However, patients with ES remain at risk for progressive disease and death. Treatment with targeted PAH therapy in ES was concerning for lowering systemic vascular resistance relative to pulmonary vascular resistance, leading to increased right to left shunting. One such target is the endothelin pathway.
Endothelin is a potent vasoactive peptide discovered in 1988 by Yanagisawa et al. 4 The effects of endothelin are mediated by Endothelin A (ET A ) and Endothelin B (ET B ) receptors. ET A receptors are located on vascular smooth muscle cells and mediate vasoconstriction. ET B receptors are on both endothelial cells and vascular smooth muscle cells. ET B receptors on endothelial cells may lead to the clearance of endothelin and production of nitric oxide, whereas ET B receptors on smooth muscle cells also mediate vasoconstriction. Several targeted therapies have been developed toward the endothelin receptors. In 2001, bosentan, a dual endothelin receptor antagonist, was approved by the US Food and Drug Administration as a treatment for group 1 PAH.
The BREATHE-5 study (Bosentan Randomized Trial of Endothelin Antagonist Therapy-5) was the first randomized, double-blind, placebo-controlled, multicenter study completed in patients with ES, with results reported in 2006.
5 Fifty-four patients with ES were randomized 2:1 to bosentan or placebo for 16 weeks. Systemic pulse oximetry did not worsen with bosentan. Bosentan reduced pulmonary vascular resistance index and mean pulmonary arterial pressure, and improved exercise capacity. Subsequent observational research suggested that targeted PAH therapy improved survival in ES.
A new-generation of endothelin receptor antagonist, macitentan, has fewer complications, requires less liver function monitoring, and is dosed daily. In this issue of Circulation, Gatzoulis and colleagues 7 evaluated macitentan in patients with ES in the MAESTRO trial (Macitentan in Eisenmenger Syndrome to Restore Exercise Capacity). MAESTRO is only the second randomized, double-blind, placebo-controlled, multicenter study to be completed in patients with ES. Patients with ES who were >12 years of age and in functional classes II to IV were randomized to placebo or macitentan for 16 weeks. The primary end point was the change from baseline in 6-minute walk distance (6-MWD). Secondary end points included the change from baseline at week 16 in functional class. Other exploratory end points were included, such as NT-proBNP (N-terminal pro-Btype natriuretic peptide) change and hemodynamic evaluation in a subgroup of patients. MAESTRO did not meet its primary end point or many secondary end points. The mean change in 6-MWD from baseline was an increase of 18.3 meters in the macitentan group and 19.7 meters in the placebo group. The 6-MWD leastsquares mean difference at week 16 was −4.7 meters between macitentan and placebo (P=0.612, intention to treat). NT-proBNP improved in the main group and pulmonary vascular resistance index and 6-MWD improved in the hemodynamic substudy.
The MAESTRO trial design was different from the BREATHE-5 study. An expanded and more heterogeneous population of patients was included in MAES-TRO: patients with more complex forms of ES, patients with Down syndrome, patients with World Health Organization functional classes II to IV, and patients with ES treated with type 5 phosphodiesterase inhibitors were included in MAESTRO. In BREATHE-5, only simple forms of ES, those in World Health Organization functional class III, and those without Down syndrome or pre-existing treatment were enrolled. In MAESTRO, 226 patients randomized 1:1 were enrolled. The majority of patients were functional class II, and 27% were receiving background phosphodiesterase type 5 therapy.
The comparison between BREATHE-5 and MAESTRO is challenging. The end points in these 2 trials were different. The BREATHE-5 study first measured pulse oximetry as the primary safety end point and pulmonary vascular resistance as the primary efficacy end point. MAESTRO evaluated 6-MWD as the primary end point and World Health Organization functional class and NTproBNP as secondary end points. It is likely that the inclusion criteria contributed to the different outcomes of these trials. Despite multiple post hoc analyses suggesting that the inclusion of a broader population with ES did not contribute to the results, an expanded population of patients with more complex forms of ES, broader World Health Organization functional class, and use of pre-existing therapy when added together suggest a different patient cohort. Further recent studies suggest that patients with Down syndrome may not respond as well to targeted PAH therapy. 8 It is impossible to predict whether macitentan treatment with the inclusion criteria in BREATHE-5 would have revealed a positive study. Both agents are dual endothelin receptor antagonists, and macitentan may have enhanced tissue specificity. Unfortunately, the differences in design cannot be overcome using post hoc analyses. A study of macitentan in a more homogenous group with similar end points will be important to determine whether macitentan is effective in treating patients with ES. This study does provide interesting insight into clinical trial design. It is known that patients with worse functional class are more likely to improve with PAH-targeted therapy. Although improvement in 6-MWD has been found to be much more modest in patients on background therapy, stronger evidence for a benefit of combination PAH therapy has subsequently been shown in multiple long-term studies with composite primary end points focused on clinical worsening, suggesting further limitation of the use of 6-MWD in patients on multiple background therapies in clinical trials. Some studies have suggested that patients with Down syndrome may not respond as well to targeted PAH therapy, as seen in the STARTS-1 study (Sildenafil in Treatment-Naïve Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension).
The MAESTRO trial brings into question the optimal trial design of targeted PAH therapy in patients with long-standing PAH. The exaggerated placebo effect in the trial may be overcome by a longer treatment time. Patients in the placebo cohort of MAESTRO had worsening pulmonary vascular resistance index over the 16 weeks, suggesting that over time these patients with ES without targeted PAH therapy would have more clinical worsening events.
Thus, the question remains: Why do 2 acceptably run randomized studies have different conclusions on the use of dual endothelin receptor antagonist drugs in ES? Little is mentioned on the difference in ET A and ET B affinity between these 2 drugs. Could it be that the much greater affinity for ET A over ET B receptors of macitentan is revealing our ignorance on the importance of the ratio on the efficacy of pulmonary vasodilation? The MAESTRO study is certainly better powered and uses the 6-MWD, which is surely a more widely available test to patients and clinicians. We would certainly not throw the baby out with the bathwater and dismiss macitentan, but we would advocate for a longer trial duration and didactic invasive evaluation of hemodynamics in a larger cohort of patients in any future study involving macitentan in this disease. We also need to evaluate the significance of the marked difference in ET A and ET B and its effect on pulmonary vasodilation.
